Is Norditropin Approved for Increasing Height?
Yes, Norditropin (somatropin), a recombinant human growth hormone from Novo Nordisk, is FDA-approved to treat growth failure in children with specific conditions causing short stature, including growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, and idiopathic short stature (ISS).[1][2] In ISS cases, it's approved for kids whose height falls below the 1.2nd percentile for age and sex, aiming to help them reach a more normal adult height.[3]
What Conditions Qualify for Height Treatment?
Norditropin targets growth disorders where height is significantly impaired:
- Growth hormone deficiency: Primary use, where the body doesn't produce enough natural GH.
- Turner syndrome: Genetic condition affecting girls, often leading to short stature.
- Prader-Willi syndrome: Causes poor growth alongside other symptoms.
- Idiopathic short stature: No identifiable cause, but height is well below average; approval came in 2003 for this off-label-like use.[2][4]
Dosing starts low (e.g., 0.024-0.034 mg/kg/day subcutaneously) and adjusts based on growth response, typically monitored every 6-12 months.[1]
How Effective Is It for Height Gain?
Clinical trials show modest gains: about 1.5-2 inches (4-6 cm) more than untreated peers over 2-3 years in GH-deficient kids, less in ISS (around 1-1.5 inches).[5] Results vary by age at start (best before puberty), adherence, and condition severity. Treatment often lasts until growth plates close, around age 14-16.[3]
Who Cannot Use Norditropin for Height?
Not approved or recommended for:
- Healthy kids seeking cosmetic height boosts—risks outweigh unproven benefits, and it's illegal off-label for this.[6]
- Active cancers, closed growth plates, or certain syndromes like Noonan.[1]
Off-label use happens but faces insurance denial and ethical scrutiny.[4]
What Are the Main Risks and Side Effects?
Common issues include injection-site reactions, headaches, joint pain, and fluid retention. Rare but serious: increased intracranial pressure, scoliosis worsening, or diabetes risk. Long-term data links it to slight cancer risk elevation in predisposed kids. Monitoring includes thyroid checks and bone age X-rays.[1][7] Cost runs $20,000-$40,000/year without insurance.[8]
When Does Treatment Stop and What Happens After?
Stops when growth velocity drops below 2 cm/year or growth plates fuse (confirmed by X-ray). Final height gains are permanent but limited; post-treatment, natural GH production may not fully recover.[5] Patents on Norditropin formulations expire variably—check DrugPatentWatch.com for specifics on U.S. exclusivity through 2030s for some delivery devices.[9]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020280s092lbl.pdf
[2] Novo Nordisk: https://www.norditropin.com
[3] Pediatrics (2008): https://publications.aap.org/pediatrics/article/122/2/471/72488/Guidelines-for-Growth-Hormone-and-Testosterone
[4] Endocrine Society Guidelines: https://academic.oup.com/jcem/article/102/10/3402/4093131
[5] NEJM (2002): https://www.nejm.org/doi/full/10.1056/NEJMoa010979
[6] AAP Policy: https://publications.aap.org/pediatrics/article/131/1/e186/30884/Use-of-Growth-Hormone-in-Pediatric-Practice
[7] Lancet (2019): https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30337-5/fulltext
[8] GoodRx: https://www.goodrx.com/norditropin
[9] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/NORDITROPIN